Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differences in gene expression of liver tissues between MAFLD patients and controls.

ABSTRACT: Differences in gene expression of liver tissues between MAFLD patients and controls.

PROVIDER: PRJNA759700 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15694270_1.fastq.gz	Fastqsanger.gz
	SRR15694270_2.fastq.gz	Fastqsanger.gz
	SRR15694271_1.fastq.gz	Fastqsanger.gz
	SRR15694271_2.fastq.gz	Fastqsanger.gz
	SRR15694272_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 50

Similar Datasets

Differences in gene expression of liver tissues between MAFLD patients and controls.

Project description:Transcriptomic analysis was applied to liver tissues of seven patients with MAFLD and nine normal controls,then, differential genes were identified by comparative analysis of sequencing results, and target genes that may be related to the pathogenesis of MAFLD were further studied.This study may provide new ideas for understanding the pathogenesis of MAFLD and thus provide new targets for the treatment of MAFLD.

2021-12-14 | GSE183229 | GEO

Bulk Liver in MAFLD/MASH

Project description:Background & Aims: Metabolic dysfunction associated steatotic liver disease (MAFLD) progresses to steatohepatitis (MASH) and is a major cause of liver cirrhosis. In the early disease stage, liver inflammation is absent. However, the early involvement of the peripheral immune cell compartments in disease progression is poorly understood and single cell profiles of peripheral immune cells in MAFLD/MASH are not known. Methods: MAFLD/MASH patients and healthy volunteers have been prospectively enrolled into a cross-sectional study. Patients have been histologically stratified and characterized by liver bulk RNA-Seq.

2025-04-30 | GSE267031 | GEO

Bulk Liver in MAFLD/MASH

Project description:Bulk Liver in MAFLD/MASH

| PRJNA1109378 | ENA

Single-cell landscape of peripheral immune cells in MAFLD/MASH [scRNA-seq]

Project description:Background & Aims: Metabolic dysfunction associated steatotic liver disease (MAFLD) progresses to metabolic dysfunction-associated steatohepatitis (MASH) and is a major cause of liver cirrhosis. Although liver inflammation is the hallmark feature of MASH vs MAFLD, the involvement of the peripheral immune cell compartments in disease progression is poorly understood and single cell profiles of peripheral immune cells in MAFLD/MASH are not known. Methods: MAFLD/MASH patients and healthy volunteers have been prospectively enrolled into a cross-sectional study. Patients have been histologically stratified and further characterized by liver bulk RNA-Seq. Peripheral immune cells from patients and control blood samples have been comprehensively profiled using bulk and single RNA-Seq. Results: 22 patients with fibrosis stage less then F3 have been histologically stratified into patients with low, medium and high disease activity score (NAS). In contrast to fibrosis, NAS group correlated with non-invasive imaging readouts and blood biomarkers of liver damage and inflammation (ALT, AST). Prevalence of type 2 diabetes and obesity was increased with NAS stage. Bulk RNA-seq profiling of patient liver biopsies revealed gene signatures that were positively and negatively associated with NAS. Known marker genes for liver fibrosis where up-regulated on RNA level. Blood bulk RNA-sequencing showed only moderate differences in patients versus healthy controls. In contrast, single cell analysis of white blood cells revealed multiple alterations of immune (sub-) populations including increased abundance of immature B-cells and myeloid suppressor cells in MAFLD/MASH patients as well as disease-association of neutrophil sub-populations.

2025-04-30 | GSE267033 | GEO

Bulk White Blood Cells in MAFLD/MASH

2025-04-30 | GSE267032 | GEO

Gene expression differences between pterygium and conjunctiva tissues

Project description:Comparison of endogenous gene expression differences between pterygium and conjunctiva tissues

2016-06-23 | GSE83627 | GEO

Gene expression differences between pterygium and conjunctiva tissues

Project description:Comparison of endogenous gene expression differences between pterygium and conjunctiva tissues RNA from donor-matched pterygium and conjunctiva tissues obtained from four patients were evaluated for differences in gene expression

2016-06-23 | E-GEOD-83627 | biostudies-arrayexpress

Hepatic lipopolysaccharide binding protein uncouples inflammation from fibrosis in MAFLD

Project description:MAFLD is a heterogenous spectrum disorder affecting 20% of the population. Inflammatory processes contribute to various stages of MAFLD and thought to instigate hepatic fibrosis. For this reason, targeting inflammation has been heavily nominated as an approach to mitigating liver fibrosis. Lipopolysaccharide binding protein is a secreted protein that plays an established role in innate immune responses. In a murine model of MAFLD, we used a liver-specific deletion of LBP model to study its role in hepatic inflammation. Single nucleus RNA-seq were applied to investigate the role of LBP in hepatic cell composition.

2024-07-15 | GSE254626 | GEO

SR-A3 suppresses AKT activation to protect against MAFLD by inhibiting XIAP-mediated PTEN degradation

Project description:Scavenger receptor class A member 3 (SR-A3) is implicated in metabolic diseases; however, the relationship between SR-A3 and metabolic dysfunction-associated fatty liver disease (MAFLD) has not been documented. Here, we show that hepatic SR-A3 expression is significantly reduced in human and animal models in the context of MAFLD. Genetic inhibition of SR-A3 in hamsters elicits hyperlipidemia, hyperglycemia, insulin resistance, and hepatic steatosis under chow-diet condition, yet escalates in diet-induced MAFLD. Mechanistically, SR-A3 ablation enhances E3 ligase XIAP-mediated proteasomal ubiquitination of PTEN, leading to AKT hyperactivation. By contrast, hepatic overexpression of human SR-A3 is sufficient to attenuate metabolic disorders in WT hamsters fed a high-fat-high-cholesterol diet and ob/ob mice via suppressing the XIAP/PTEN/AKT axis. In parallel, pharmacological intervention by PTEN agonist oroxin B or lipid lowering agent ezetimibe differentially corrects MAFLD in hamsters.

2025-02-13 | GSE289495 | GEO

Transcriptome differences between brown adipose tissues of wildtype and UCP1-KO mice

Project description:Transcriptome differences between brown adipose tissues of wildtype and UCP1-KO mice

| PRJNA503812 | ENA